Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Russian, Korean Pharmas Lead $42.5M Argos Financing, Take Local Rights

This article was originally published in The Pink Sheet Daily

Executive Summary

The personalized immunotherapy developer partnered with two foreign pharmas but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.

You may also be interested in...



Clinical Data In 2014 Could Trigger Private Biotech Financings

Despite difficulties financing late-stage trials, several private companies are expecting Phase II and III data that should help shape public investor sentiment this year. Familiar compounds in new guises lead the way.

Six Life Science Bets For 2014

2014 is not even a week old, but several privately-held companies have made resolutions to enter the public market this year, building on the momentum of a strong IPO market in 2013.

Financings Of The Fortnight: Cutting-Edge Biomedical Technology Drawing Big Investments

Juno Therapeutics and Moderna Therapeutics both leveraged promising technologies to bring home venture rounds of more than $100 million in recent weeks. Plus news on recent financings by Argos Therapeutics, Xencor, Sitari and 5am Ventures.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel